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Summary
Hormone replacement therapy (HRT) has been shown to increase
the relative risk of idiopathic venous thromboembolism (VTE) about
threefold in several observational studies and one randomised con-
trolled trial. Whether or not this relative risk is higher in women with
underlying thrombophilia phenotypes, such as activated protein C
(APC) resistance, is unknown. We therefore restudied the participants
in a case-control study of the relationship between the use of HRT and
the occurrence of idiopathic VTE in women aged 45-64 years. After
protocol exclusions, 66 of the cases in the original study and 163 of the
controls were studied. Twenty haematological variables relevant to risk
of VTE were analysed, including thrombotic states defined from the
literature. The relative risk of VTE showed significant associations
with APC resistance (OR 4.06; 95% CI 1.62, 10.21); low antithrombin
(3.33; 1.15, 9.65) or protein C (2.93; 1.06, 8.14); and high coagulation
factor IX (2.34; 1.26, 4.35), or fibrin D-dimer (3.84; 1.99, 7.42). HRT
use increased the risk of VTE in women without any of these thrombot-
ic states (OR 4.09; 95% CI 1.26, 13.30). A similar effect of HRT use on
the relative risk of VTE was also found in women with prothrombotic
states. Thus for example, the combination of HRT use and APC resist-
ance increased the risk of VTE about 13-fold compared with women of
similar age without either APC resistance or HRT use (OR 13.27; 95%
CI 4.30, 40.97).
We conclude that the combination of HRT use and thrombophilias
(especially if multiple) increases the relative risk of VTE substantially;
hence women known to have thrombophilias (especially if multiple)
should be counselled about this increased risk prior to prescription of
HRT. However, HRT increases the risk of VTE about fourfold even in
women without any thrombotic abnormalities: possible causes are dis-
cussed.
Introduction
In premenopausal women, the risk of venous thromboembolism
(VTE) increases during pregnancy and the puerperium (1) and use of
combined oral contraceptive pills (2), possibly due to complex effects
of oestrogens and progestogens upon haematological variables related
to blood coagulation, fibrinolysis and rheology (1, 3). In peri- and post-
menopausal women, recent evidence from several epidemiological
studies and one clinical trial suggests that use of hormone replacement
therapy (HRT) increases the risk of idiopathic VTE about threefold
(4-9). The mechanisms are not established, but as with oral contra-
ceptives may reflect complex effects of HRT upon haematological
variables (10-12), including activated protein C (APC) resistance (12).
Blood coagulation screening has been suggested to identify underlying
prothrombotic states (thrombophilias), at least in women considering
HRT who have a personal or family history of venous thromboembo-
lism (13). With increasing use of HRT, however, widespread screening
would involve major costs for potential benefits which have not been
defined.
To identify the associations of prothrombotic states with VTE, and
their interactions with HRT for risk of VTE, we studied 20 haematolog-
ical variables related to thrombotic risk in a follow-up of a hospital-
based case-control study of idiopathic VTE in women aged 45-64 years
(4).
Subjects and Methods
The original case-control study has been reported previously (4). Briefly,
cases were 103 women aged 45-64 years who were admitted to hospital
between April 1990 and December 1994 in the old Oxford Regional Health
Authority area with a main diagnosis of first-episode of deep vein thrombosis
(DVT) or pulmonary embolism (PE); and who had no past history of stroke,
myocardial infarction, or certain cancers; or of pregnancy, surgical operation,
severe trauma or illness necessitating bed rest for longer than one week in the
6 weeks prior to admission. Hospital controls (178 in number) were recruited
from among women admitted to hospital with a diagnosis judged to be unrelat-
ed to HRT use in the study age group. Up to two controls were recruited per
case, matched by 5-year age group, district of admission and date of admission.
Exclusion criteria were as for cases.
For the follow-up study, all surviving cases and controls were invited for
interview in their general practitioner’s surgery or at home, between June 1995
and July 1996. After explanation and informed consent, a questionnaire was
administered which enquired about intercurrent illnesses including VTE, cur-
rent drug use including HRT and anticoagulants, and smoking habit. Height and
weight were recorded as before (4).
20 ml of venous blood was sampled from an antecubital vein and anticoag-
ulated with trisodium citrate (0.11 M: 9:1 v:v) or K2 EDTA (1.5 mg/ml).
K2 EDTA blood samples were sent to the Glasgow laboratory by first-class post
for assays of whole-blood and plasma viscosities and haematocrit as described
previously (14), and for extraction of DNA for subsequent genetic analyses.
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Citrated plasma samples were centrifuged the same day, aliquotted and stored
locally at –50° C prior to courier transport to the Glasgow laboratory on dry ice.
Plasma activities of fibrinogen (Clauss assay); coagulation factors VII, VIII and
IX; and coagulation inhibitors (antithrombin, protein C and protein S), were
measured as previously described (15); as were the activated partial thrombo-
plastin time (APTT) and activated protein C ratio (12) (a low APC ratio indi-
cates APC resistance). The coagulation activation markers, prothrombin frag-
ment F1+2 and thrombin-antithrombin complexes (TAT) were measured using
ELISAs (Behringwerke, Marburg, Germany) (15). Plasma levels of von Wille-
brand factor antigen (vWF), fibrin D-dimer antigen, tissue plasminogen activa-
tor antigen (tPA) and plasminogen activator inhibitor activity (PAI) were
measured as previously reported (16). Prothrombin time (PT) and PT-derived
fibrinogen were measured in an ACL 300 research coagulometer (Instrumenta-
tion Laboratory, Warrington) (17) using the manufacturer’s standards.
Statistical analysis. Between the time of the original study (4) and the
follow-up study, several cases or controls lost their matched partners, due to
non-availability for re-study, or to development of exclusion criteria from the
original study (certain cancers, coronary heart disease, stroke, oral contracep-
tive use; or VTE in controls). Rather than exclude these unmatched women, a
stratified, unmatched analysis, was performed. Generalised linear models were
fitted, controlling for the matching variables from the initial study: age, area of
admission to hospital, and time of diagnosis (4).
Thrombophilias were defined as levels of APC ratio (12), antithrombin,
protein C or protein S below the laboratory’s 95th percentile for age- and sex-
matched controls. Other thrombotic states were derived from the literature as
follows: fibrinogen 4 g/l (17, 20, 22); factor VIII 150 iu/dl (18); the same
cut-off point for factor VIII was assigned for vWF, factor VII, and factor IX
which have similar population distributions (15), APTT 25 s (24), and D-
dimer 250 ng/ml (24). Obesity (body mass index 30 kg/m2) was also stud-
ied in view of its association with VTE in women (25).
The study was approved by local Research Ethics Committees, and written,
informed consent was obtained from all subjects.
Results
80 cases and 171 controls from the original case-control study (4)
attended for re-study. 14 cases were excluded from analysis because of
cancer (2), coronary heart disease (1), or current oral anticoagulant
use (11) which affects several assays of thrombotic variables, leaving
66 cases. 8 controls were excluded because of intercurrent VTE (2),
cancer (3), coronary heart disease (1) or current OC use (2), leaving
163 controls. In the case group, 18 of 32 HRT users at the time of their
thromboembolic event had stopped HRT use at the time of the follow-
up study, while 2 of 34 non-users had commenced HRT use. In the con-
trol group, the corresponding numbers were 5 of 39 HRT users and 18
of 124 non-users. At the time of re-study, 50 eligible cases were not
using HRT, 6 were using combined oral oestrogen and progestogen
preparations, 5 were using unopposed oral oestrogen, and 5 were using
patches. Of the 163 eligible controls, the corresponding numbers were
111, 21, 20 and 10, plus one woman taking Livial. As in the original
study (4), cases had a higher body mass index than controls (mean
difference = 1.4 kg/m2, p = 0.06). There were no significant (p 0.05)
differences in smoking habit between cases and controls (data not
shown).
We first examined the data to see if we could detect any effect of cur-
rent HRT use on any of the thrombotic variables. For this purpose, we
compared the 50 cases who were not using HRT at the time of blood
sampling with the 16 cases who were, and the 111 controls who were
not using HRT at the time of blood sampling with the 52 who were.
The results are shown in Tables 1 and 2. No statistically significant
differences were observed. Current HRT use was thus not taken into
account in subsequent analyses.
Table 3 shows the mean levels of thrombotic variables in cases
and controls, after adjustment for age, area and date of admission to
the study. Cases of VTE had significantly higher activated protein C
(APC) resistance (defined as a lower APC ratio) and von Willebrand
factor antigen, as well as significantly lower plasma antithrombin
activity.  Notable but non-significant associations were observed for
fibrinogen (PT-derived assay), factor VIII, factor IX, protein C, and
D-dimer.
Table 4 shows the association of VTE with defined thrombotic states
with the variables treated as dichotomies. The odds ratios are shown
adjusted for age, area and date of admission to the study and addition-
ally adjusted for HRT use at the time of the index event as well. It can
be seen that inclusion of the last mentioned variable has very little
effect on the odds ratios. The strongest association of VTE was
with APC resistance (APC ratio 2; OR 4.06 [95% CI 1.62, 10.21];
p = 0.003). Low levels of antithrombin (90 iu/dl; OR 3.33 [1.15, 9.65]
p = 0.03) or protein C (80 iu/dl OR 2.93 [1.06, 8.14]; p = 0.04) were
also associated with VTE, as were high levels of D-dimer (250 ng/ml;
OR 3.84 [1.99, 7.42], p = 0.006) and factor IX (150 iu/dl; OR 2.34
[1.26, 4.35]; p = 0.007). Non-significant associations (OR 1.40-1.81)
were observed for fibrinogen, factor VIII, vWF and APTT. The
association with obesity (BMI 30 kg/m2) was also non-significant
Table 1 Mean (95% CI) levels of thrombotic variables
among cases of VTE according to use of HRT at time of
blood sampling, and in controls according to use of
HRT at time of blood sampling. Coagulation factors,
coagulation times and APC ratio
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(OR 1.39). No association of VTE was observed with high factor VII or
low protein S activities.
101 women had no potential thrombotic risk factor for VTE, taking
into account only those factors with a significant effect in Table 4, that
is either a “low” APC ratio, antithrombin or protein C level; or a “high”
level of factor IX or D-dimer. Of these, 17 were cases (8 were HRT
users at the index event) and 84 were controls (20 were HRT users at
the index event). The odds ratio for the association of HRT with VTE
in this sub-group was 4.09 (95% CI 1.26, 13.30; p = 0.02), very similar
to the odds ratio in the whole group (3.37; 1.79, 6.34; p = 0.0002).
Multiple logistic regression analysis was undertaken and the number
of thrombotic variables with a significant relationship with VTE was
reduced from 5 to 3. Protein C became non-significant given APC
ratio (p = 0.18); while D-dimer became non-significant (p = 0.11)
given APC ratio and factor IX. A statistical model was developed to
predict the odds ratio for VTE for single and combined abnormalities of
APC resistance, low antithrombin and high factor IX; in the presence
and absence of HRT use at the index event (Fig. 1). In the absence of
HRT use, when the baseline risk of VTE was defined as 1 in women
without any of the three coagulation abnormalities, the risk rose
slightly in the presence of one abnormality; increased considerably in
the presence of two abnormalities; and increased still further in the
presence of all three abnormalities to an odds ratio of 47.5 (95% CI
8.95, 252). The figure predicts that, at any level of risk attributable to
the effects of thrombotic variables, HRT use consistently increases this
risk approximately threefold, that is the odds ratios are independent and
multiplicative. In the extreme case of HRT use in a woman with APC
resistance, antithrombin deficiency, and high factor IX, the predicted
odds ratio for VTE is 153 (95% CI 23.5, 1001).
Fig. 1 Odds ratios for risk of idiopathic venous thromboembolism (taking
non-users of HRT with no identified coagulation abnormality as the baseline
group), in non-users of HRT (solid line) and users of HRT (broken line).
hiFIX = high factor IX; low AT = low antithrombin; APCrs = activated pro-
tein C resistance
Table 2 Mean (95% CI)
levels of thrombotic vari-
ables among cases of VTE
according to use of HRT at
time of blood sampling, and
in controls according to use
of HRT at time of blood
sampling. Coagulation in-
hibitors, activation markers,
fibrinolysis and rheology
variables
Table 3 Mean (95% confidence interval) for haematological variables in
cases and controls after adjustment for age, area and date of admission to study
Note: values shown are back-transformed after analysis on log scale (Clauss 
fibrinogen, factor VIII, vWF, APC ratio, TAT, D-dimer, tPA, blood and
plasma viscosity), square root scale (PT derived fibrinogen, factor IX,
F1+2), reciprocal scale (APTT) and after raising to the power 1/10 (PAI)
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Discussion
The present report appears to be the first systematic study to investi-
gate the relationships between HRT use, idiopathic VTE, and thrombo-
philias (defined as changes in haemostatic phenotypes associated with
increased risk of VTE) in peri- and post-menopausal women. Our find-
ings that the risk of idiopathic VTE is increased in such women by
either activated protein C (APC) resistance, or low antithrombin or pro-
tein C activity, are consistent with those of the Leiden Thrombophilia
Study, a case-control study of men and women aged 16-73 years (21,
23), as well as with those of other epidemiological, family and genetic
studies (26). Positive but non-significant trends for an association of
VTE with high fibrinogen or factor VIII/vWF levels were observed,
which are consistent with results from the Leiden Study (21, 22). We
observed no association of low protein S or high factor VII with VTE,
as in the Leiden Study (21, 22).
We report two novel laboratory associations of idiopathic VTE: high
levels of coagulation factor IX, and of fibrin D-dimer. The association
of high factor IX levels with VTE is biologically plausible, because of
the association of VTE and laboratory evidence of hypercoaguability
following infusion of prothrombin complex concentrates in factor IX-
deficient haemophiliacs (27). Fibrin D-dimer is a marker of increased
turnover (formation and lysis) of cross-linked fibrin, which is associat-
ed with incident venous (24) and arterial (16) thrombosis. However the
association of D-dimer with VTE became non-significant after allow-
ing for the effects of APC resistance and factor IX. Elevated D-dimer
levels are normalised by warfarin, which lowers levels of vitamin-K-
dependent coagulation factors including factor IX (28, 29); hence it is
possible that D-dimer levels are a marker of other hypercoagualable
states (APC resistance, high factor IX) or of previous VTE.
Our prediction from the statistical model that the risk of idiopathic
VTE increases with combined APC resistance and low antithrombin
accords with the increased risk observed in persons with combined
relevant genetic abnormalities (26). The model also predicts that the
combination of either of these coagulation inhibitor deficiencies with
high factor IX levels increases risk of VTE. In accordance with this pre-
diction, infusion of prothrombin complex concentrates in patients with
liver failure (who have low plasma antithrombin levels) was associated
with a high risk of thrombosis (30). The combination of high factor IX
with deficiencies in both coagulation inhibitor systems (APC resistance
plus antithrombin deficiency) is predicted to carry a very high risk of
VTE; however data to substantiate this high predicted risk will be diffi-
cult to obtain because of the rarity of this combination of risk associa-
tions.
What is the relevance of these associations of prothrombotic states
with VTE to prescription of HRT in women aged 45-64 years? Our data
suggest that the effect of HRT use is to increase, approximately three-
to fourfold, the relative risk of VTE, regardless of underlying pro-
thrombotic states. This implies that the absolute risk of VTE will be
strongly affected by the presence of underlying prothrombotic states,
especially if multiple.
The Leiden Study observed a multiplicative effect of oral contracep-
tive use and the factor V Leiden mutation (an important determinant of
APC resistance) on risk of venous thromboembolism (odds ratio 34.7;
95% CI 7.8-154) compared with women without this mutation who
were not users of oral contraceptives (23). In the present study, we have
found a similar multiplicative effect of HRT use and APC resistance
in peri- and post-menopausal women (odds ratio 13.27; 95% CI 4.30,
40.97) compared with women without this phenotype who were not
users of HRT. It has recently been reported from the Leiden Study that
the APC resistance phenotype is associated with DVT, independently
of the factor V Leiden mutation (31). Likewise, the ECAT DVT study
observed that the APC resistance phenotype was an independent pre-
dictor of DVT after hip replacement surgery, on multivariate analysis
(32).
In studies of biological effects, HRT has been associated not only
with increased APC resistance (12); but also with lower plasma anti-
thrombin levels (10, 11). Recently, Bloemenkamp et al. (33) reported
that in women with a history of DVT, current oral contraceptive use
was associated with more pronounced effects on APC resistance, anti-
thrombin, protein C and factor VII levels than in women without a
history of DVT. In the present study, we did not observe significant dif-
ferences between VTE cases and controls in the effects of current HRT
use on any thrombotic test studied (Tables 1 and 2). It must be stressed,
however, that the present study was small and had little power to detect
small differences.
We observed that HRT increased the risk of idiopathic VTE approx-
imately fourfold in women without any of the thrombotic abnormalities
we took into consideration. This finding suggests that HRT use is not
simply precipitating VTE in predisposed, thrombophilic women, but is
exerting a more general effect on risk of VTE, at any level of thrombot-
ic risk factors. Possible mechanisms include venodilatation, which has
Table 4 Odds ratios for
venous thromboembolism
when variables are treated
as dichotomies
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been associated with risk of postoperative DVT (34). It is interesting
to note that VTE is commoner in premenopausal women than in men
of similar age (35), and to speculate that the “increased risk” of VTE
with HRT may be not so much an adverse effect of a drug, but rather a
perpetuation of the premenopausal oestrogenic state. From the view-
point of total cardiovascular risk, such a state may in general confer a
threefold increased risk of VTE, which would be outweighed by the
one-third decreased risk of myocardial infarction observed in epidemi-
ological studies if this effect can be confirmed in controlled trials.
Nevertheless, our findings suggest that the absolute risk of VTE may be
high in women with certain thrombophilias who use HRT: routine
counselling on relative thrombotic risks in such women may have to be
modified. We suggest that further studies be performed to determine
more precisely the interactions of HRT use and predisposing factors for
VTE: we are currently studying the influence of relevant genotypes, as
well as the phenotypes reported in the present paper. The relative
thrombotic risks of HRT and effects of different HRT preparations
should also be studied, as well as the possible benefits, risks and
costs of coagulation screening prior to HRT prescription. At present, it
appears reasonable to confine such screening to the minority of women
(under 1%) who have a past history or family history of VTE (13).
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